Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spectacular Market Launches Key To Enduring Success Of Brands In Asia - IMS Health

This article was originally published in The Pink Sheet Daily

Executive Summary

Data show that "pharmerging" markets, will grow at 14-17%, while the U.S. will lag with 3-6% growth, Europe will grow at an even slower rate of 1-4% and Japan will move at 2-5% in the next four years, underscoring the importance of Asian markets, IMS stresses.

You may also be interested in...



"Roche May Be Right" In Not Taking To Generic Drugs - IMS Health; "Innovation Surge" From 2016 Will Help Big Pharma

MUMBAI - Global pharmaceutical companies - traditionally originators of blockbuster drugs - may not be expected to become part of a "long list of generic players" even by 2020, according to leading industry data and consulting firm IMS Health. However, experts believe MNCs will pursue specific areas where their skill sets can offer competitive advantages

Western Companies' Perspectives On Emerging Markets: Execution Trumps Strategy - PharmAsia Summit

SAN FRANCISCO - Western companies expanding in emerging markets are likely to distinguish themselves from competitors by successful execution and understanding of local markets, more so than by broad strategic differences, according to participants on a panel on Big Pharma perspectives on emerging markets at Elsevier Business Intelligence's PharmAsia Summit, held Oct. 26 in San Francisco

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel